Aprea Therapeutics

Company snapshot

Aprea Therapeutics (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. We exist to ensure that cancer doesn't interrupt life's possibilities and dreams. We do this through our unique approach to synthetic lethality that is revolutionizing the future of cancer treatment.

• 15 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 US patent(s) indexed to this assignee profile.
• 15 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Aprea Therapeutics. Not investment advice.

• Peer + 0 momentum

  Arcus Biosciences

  TA overlap score 30.6

• Peer + 0 momentum

  PMV Pharmaceuticals

  TA overlap score 21.2

Recent activity

Latest pipeline, patent, and corporate events for Aprea Therapeutics.

1. Jun 8, 2026 Clinical update

   APR-246 — Phase 2

2. Jun 5, 2026 Clinical update

   APR-246 — Phase 1

3. May 23, 2026 Clinical update

   APR-246 + azacitidine — Phase 3

4. May 23, 2026 Clinical update

   APR-246 — Phase 2

5. May 23, 2026 Clinical update

   APR-246 — Phase 2

View all clinical trial activity →

• What is Aprea Therapeutics?

  Aprea Therapeutics is a pharma organization headquartered in Doylestown, USA. It trades on NYSE under ticker APRE. Primary therapeutic focus areas include Advanced Solid Tumor, Acute Myeloid Leukemia or Myelodysplastic Syndromes, Non Hodgkin Lymphoma, Bladder Cancer, Hematologic

• Is Aprea Therapeutics publicly traded?

  Yes. Aprea Therapeutics is listed with ticker APRE on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Aprea Therapeutics develop or market?

  We link 5 drug profile(s) where Aprea Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aprea-therapeutics#company-drugs.

• What are the latest developments for Aprea Therapeutics?

  In the last 12 months our linked public records show 15 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Aprea Therapeutics focus on?

  Aprea Therapeutics focuses on Advanced Solid Tumor, Acute Myeloid Leukemia or Myelodysplastic Syndromes, Non Hodgkin Lymphoma based on our analysis of their pipeline programs and drug development activities.